[{"address1": "One Corporate Drive", "address2": "2nd Floor", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "800-466-6059", "website": "https://www.aligos.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-\u00df agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 70, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lawrence M. Blatt MBA, Ph.D.", "age": 62, "title": "CEO, President & Chairman of the Board", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 1006234, "exercisedValue": 0, "unexercisedValue": 228334}, {"maxAge": 1, "name": "Dr. Julian A. Symons DPHIL", "age": 62, "title": "Executive VP & Chief Scientific Officer", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 677467, "exercisedValue": 0, "unexercisedValue": 52440}, {"maxAge": 1, "name": "Ms. Kristina  Engeseth M.B.A.", "title": "Senior VP and Head of People & Culture", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sushmita M. Chanda DABT, Ph.D.", "age": 57, "title": "Executive Vice President & Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David B. Smith Ph.D.", "title": "Executive VP & Head of Chemical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tse-I  Lin Ph.D.", "title": "Senior VP of Early Compound Development & Belgian Site Head", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hardean E. Achneck M.D.", "age": 47, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.36, "open": 4.36, "dayLow": 4.2, "dayHigh": 4.89, "regularMarketPreviousClose": 4.36, "regularMarketOpen": 4.36, "regularMarketDayLow": 4.2, "regularMarketDayHigh": 4.89, "payoutRatio": 0.0, "beta": 2.763, "forwardPE": -0.40184563, "volume": 117057, "regularMarketVolume": 117057, "averageVolume": 182540, "averageVolume10days": 116840, "averageDailyVolume10Day": 116840, "bid": 4.66, "ask": 4.98, "bidSize": 1, "askSize": 1, "marketCap": 29289892, "fiftyTwoWeekLow": 3.76, "fiftyTwoWeekHigh": 46.8, "priceToSalesTrailing12Months": 7.4245605, "fiftyDayAverage": 8.5351, "twoHundredDayAverage": 16.6007, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -20560456, "profitMargins": 0.0, "floatShares": 4373872, "sharesOutstanding": 5314800, "sharesShort": 831999, "sharesShortPriorMonth": 795342, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.1361, "heldPercentInsiders": 0.10442001, "heldPercentInstitutions": 0.34183997, "shortRatio": 4.58, "shortPercentOfFloat": 0.2031, "impliedSharesOutstanding": 6114800, "bookValue": -7.497, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -131211000, "trailingEps": -20.94, "forwardEps": -11.92, "lastSplitFactor": "1:25", "lastSplitDate": 1724025600, "enterpriseToRevenue": -5.212, "enterpriseToEbitda": 0.233, "52WeekChange": -0.77554697, "SandP52WeekChange": 0.08001411, "quoteType": "EQUITY", "currentPrice": 4.79, "targetHighPrice": 175.0, "targetLowPrice": 36.0, "targetMeanPrice": 90.33333, "targetMedianPrice": 60.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 56939000, "totalCashPerShare": 9.312, "ebitda": -88127000, "totalDebt": 8375000, "quickRatio": 2.619, "currentRatio": 2.859, "totalRevenue": 3945000, "revenuePerShare": 0.63, "returnOnAssets": -0.50285, "returnOnEquity": -4.15837, "grossProfits": -66324000, "freeCashflow": -46987248, "operatingCashflow": -80743000, "revenueGrowth": -0.765, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -32.69157, "financialCurrency": "USD", "symbol": "ALGS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1602855000000, "shortName": "Aligos Therapeutics, Inc.", "longName": "Aligos Therapeutics, Inc.", "corporateActions": [], "regularMarketTime": 1746724408, "exchange": "NCM", "messageBoardId": "finmb_581475891", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChange": 0.42999983, "regularMarketDayRange": "4.2 - 4.89", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 182540, "fiftyTwoWeekLowChange": 1.03, "fiftyTwoWeekLowChangePercent": 0.27393615, "fiftyTwoWeekRange": "3.76 - 46.8", "fiftyTwoWeekHighChange": -42.01, "fiftyTwoWeekHighChangePercent": -0.8976495, "fiftyTwoWeekChangePercent": -77.554695, "earningsTimestamp": 1746532800, "earningsTimestampStart": 1754305140, "earningsTimestampEnd": 1754654400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -20.94, "epsForward": -11.92, "epsCurrentYear": -6.695, "priceEpsCurrentYear": -0.7154593, "fiftyDayAverageChange": -3.7451, "fiftyDayAverageChangePercent": -0.43878806, "twoHundredDayAverageChange": -11.8107, "twoHundredDayAverageChangePercent": -0.71145797, "priceToBook": -0.6389222, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-10-16", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "regularMarketChangePercent": 9.862382, "regularMarketPrice": 4.79, "marketState": "REGULAR", "displayName": "Aligos Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-08"}]